Sutro Biopharma (STRO) News Today $0.91 +0.11 (+14.38%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Sutro Biopharma (NASDAQ:STRO) Upgraded by Piper Sandler to Overweight RatingPiper Sandler raised Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective on the stock in a research note on Monday.June 16 at 8:17 AM | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by AnalystsShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold ratingJune 16 at 1:35 AM | marketbeat.comSutro Biopharma upgraded to Overweight from Neutral at Piper SandlerJune 16 at 1:03 AM | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLCMillennium Management LLC cut its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 80.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 405,618 shares of the company's stock aJune 7, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 6,860,000 shares, an increase of 28.5% from the April 30th total of 5,340,000 shares. Based on an average daily volume of 1,870,000 shares, the short-interest ratio is currently 3.7 days. Approximately 8.8% of the shares of the company are short sold.June 3, 2025 | marketbeat.comSutro Biopharma Appoints Greg Chow as Chief Financial OfficerJune 2, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has received a consensus rating of "Hold" from the eight brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating toMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)Point72 Asset Management L.P. trimmed its position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 26.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,197,538 shares of the company's stock after sellingMay 22, 2025 | marketbeat.com2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LPVestal Point Capital LP purchased a new position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,570,000 shares of the company's stock, valued at aMay 21, 2025 | marketbeat.comSuvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)Suvretta Capital Management LLC increased its position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 3.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,462,495 shares of the company's stock after pMay 19, 2025 | marketbeat.comMPM Bioimpact LLC Has $3.98 Million Position in Sutro Biopharma, Inc. (NASDAQ:STRO)MPM Bioimpact LLC decreased its position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 23.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,160,062 shares of the company's stock after selling 672,002 shares during the quarter. MPMMay 16, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Releases Earnings Results, Misses Expectations By $0.28 EPSSutro Biopharma (NASDAQ:STRO - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.28). The business had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%.May 14, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma (STRO) Expected to Announce Quarterly Earnings on MondaySutro Biopharma (NASDAQ:STRO) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-sutro-biopharma-inc-stock/)May 7, 2025 | marketbeat.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comSutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC WainwrightHC Wainwright reiterated a "neutral" rating and set a $2.00 price objective on shares of Sutro Biopharma in a research report on Tuesday.May 1, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from AnalystsShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have received a consensus recommendation of "Hold" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating andApril 28, 2025 | marketbeat.comHC Wainwright Lifts Earnings Estimates for Sutro BiopharmaSutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research note issued to investors on Monday, March 17th. HC Wainwright analyst A. Fein now anticipates that tMarch 20, 2025 | marketbeat.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 17, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma (NASDAQ:STRO) Downgraded to Market Perform Rating by Citizens JmpCitizens Jmp lowered shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a research report on Friday.March 15, 2025 | marketbeat.comWedbush Downgrades Sutro Biopharma (NASDAQ:STRO) to NeutralWedbush cut shares of Sutro Biopharma from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $8.00 to $2.00 in a research report on Friday.March 15, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Lowered to "Underperform" Rating by Bank of AmericaBank of America lowered Sutro Biopharma from a "buy" rating to an "underperform" rating and cut their target price for the company from $11.00 to $1.00 in a report on Friday.March 15, 2025 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Announces Earnings ResultsSutro Biopharma (NASDAQ:STRO - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($2.96) earnings per share for the quarter. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%.March 14, 2025 | marketbeat.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comSutro drops as portfolio review leads to downgradesMarch 14, 2025 | msn.comSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 14, 2025 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC PipelineMarch 14, 2025 | finanznachrichten.deSutro Biopharma downgraded to Neutral from Outperform at WedbushMarch 14, 2025 | markets.businessinsider.comSutro Biopharma double downgraded at BofA after luvelta deprioritizedMarch 14, 2025 | markets.businessinsider.comSutro Biopharma Review Results in 50% Workforce Reduction, CEO TransitionMarch 14, 2025 | marketwatch.comSutro Biopharma (STRO) was downgraded to a Hold Rating at JMP SecuritiesMarch 14, 2025 | markets.businessinsider.comSutro Biopharma rises after market hours on portfolio review, restructuringMarch 14, 2025 | msn.comSutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 13, 2025 | globenewswire.comSutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC PipelineMarch 13, 2025 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of "Moderate Buy" by AnalystsSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy reMarch 8, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. cut its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 96.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,791 shares of the company's stock after selling 1,470,550 sFebruary 19, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Average Target Price from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the companyFebruary 14, 2025 | marketbeat.comSutro Biopharma stock hits 52-week low at $1.67 amid market challengesFebruary 11, 2025 | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issuedFebruary 11, 2025 | marketbeat.comWe're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn RateJanuary 22, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus Target Price from BrokeragesShares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on tJanuary 20, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recJanuary 17, 2025 | marketbeat.comSutro Biopharma (STRO) Gets a Buy from Bank of America SecuritiesJanuary 17, 2025 | markets.businessinsider.com Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address STRO Media Mentions By Week STRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STRO News Sentiment▼0.830.90▲Average Medical News Sentiment STRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STRO Articles This Week▼52▲STRO Articles Average Week Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Corvus Pharmaceuticals News Atea Pharmaceuticals News Immutep News 2seventy bio News Inozyme Pharma News Cardiff Oncology News Foghorn Therapeutics News Amarin News Aardvark Therapeutics News Lifecore Biomedical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STRO) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STRO Stock Free STRO Stock Alerts